Brief: Infinity Pharmaceuticals Inc Encouraging Updated Data From Phase 2 MARIO-3 TNBC Trial Presented At 2021 San Antonio Breast Cancer Symposium
10/12/2021 13:01
Dec 10 (Reuters) - Infinity Pharmaceuticals Inc INFI.O :
* ENCOURAGING UPDATED DATA FROM PHASE 2 MARIO-3 TNBC TRIAL
PRESENTED AT 2021 SAN ANTONIO BREAST CANCER SYMPOSIUM
* INFINITY PHARMACEUTICALS INC - 88.6% OF EVALUABLE 1L TNBC
PATIENTS ACHIEVED TUMOR REDUCTION
* INFINITY PHARMACEUTICALS INC - DISEASE CONTROL RATE OF
92.8% AND
81.4% OF EVALUABLE PATIENTS WITH PD-L1 POSITIVE AND PD-L1
NEGATIVE TUMORS, RESPECTIVELY
* INFINITY PHARMACEUTICALS INC - SAFETY CONSISTENT WITH
EXPECTATIONS FOR THREE COMPONENT DRUGS WITH NO NEW SAFETY
SIGNALS
* INFINITY PHARMACEUTICALS - MEDIAN PFS IMPROVEMENT OF 47%
AND 30%
VERSUS IMPASSION130 BENCHMARK FOR PATIENTS WITH PD-L1 POSITIVE
AND PD-L1 NEGATIVE TUMORS
Source text for Eikon: ID:nBw8Kl51pa
Further company coverage: INFI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Infinity Pharmaceuticals
See all newsBrief: Infinity Pharmaceuticals Filed Voluntary Petition For Relief Under Provisions Of Chapter 11
Brief: Infinity Pharmaceuticals Inc Received Determination Letter From Nasdaq On September 12
Brief: Infinity Pharma Says On Sept 5, 2023, Co Received Letter From Nasdaq Notifying That Listing Of Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Infinity Pharmaceuticals Approved Plan To Reduce Co's Overall Headcount By 21 Positions
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX